Gsa Capital Partners LLP Nuvation Bio Inc. Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
A detailed history of Gsa Capital Partners LLP transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 242,253 shares of NUVB stock, worth $552,336. This represents 0.05% of its overall portfolio holdings.
Number of Shares
242,253
Previous 74,932
223.3%
Holding current value
$552,336
Previous $172,000
274.42%
% of portfolio
0.05%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding NUVB
# of Institutions
166Shares Held
164MCall Options Held
3.2KPut Options Held
98.7K-
Decheng Capital LLC Menlo Park, CA26MShares$59.2 Million14.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA19.2MShares$43.8 Million1.92% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$37 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.7MShares$35.9 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.1MShares$29.8 Million44.61% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $495M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...